Liver Transplantation in the United States, 1999–2008 by Thuluvath, P. J. et al.
American Journal of Transplantation 2010; 10 (Part 2): 1003–1019
Wiley Periodicals Inc.
No claim to original US government works
Journal compilation C© 2010 The American Society of
Transplantation and the American Society of Transplant Surgeons
doi: 10.1111/j.1600-6143.2010.03037.xSpecial Feature
Liver Transplantation in the United States, 1999–2008
P. J. Thuluvatha,b,*, M. K. Guidingerc,d,
J. J. Funge, L. B. Johnsonb, S. C. Rayhillf
and S. J. Pelletierc,g
aMercy Medical Center, Baltimore, MD
bGeorgetown University Hospital, Washington, DC
cScientific Registry of Transplant Recipients, Ann Arbor,
MI
dArbor Research Collaborative for Health, Ann Arbor, MI
eCleveland Clinic, Cleveland, OH
fCenter for Health and Healing, Oregon Health and
Science University, Portland, OR
gUniversity of Michigan, Ann Arbor, MI
*Corresponding author: Paul J. Thuluvath,
thuluvath@gmail.com
Note on sources: The articles in this report are based on
the reference tables in the 2009 OPTN/SRTR Annual
Report. Table numbers are noted in brackets and may be
found online at: http://ustransplant.org.
Changes in organ allocation policy in 2002 reduced the
number of adult patients on the liver transplant wait-
ing list, changed the characteristics of transplant re-
cipients and increased the number of patients receiv-
ing simultaneous liver–kidney transplantation (SLK).
The number of liver transplants peaked in 2006 and
declined marginally in 2007 and 2008. During this pe-
riod, there was an increase in donor age, the Donor
Risk Index, the number of candidates receiving MELD
exception scores and the number of recipients with
hepatocellular carcinoma. In contrast, there was a de-
crease in retransplantation rates, and the number of
patients receiving grafts from either a living donor or
from donation after cardiac death. The proportion of
patients with severe obesity, diabetes and renal insuf-
ficiency increased during this period. Despite increases
in donor and recipient risk factors, there was a trend to-
wards better 1-year graft and patient survival between
1998 and 2007. Of major concern, however, were con-
siderable regional variations in waiting time and post-
transplant survival. The current status of liver trans-
plantation in the United States between 1999 and 2008
was analyzed using SRTR data. In addition to a general
summary, we have included a more detailed analysis of
liver transplantation for hepatitis C, retransplantation
and SLK transplantation.
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Introduction
Adoption of model for end-stage liver disease (MELD)
scores, pediatric end-stage liver disease (PELD) scores and
further provision of priority scores for hepatocellular carci-
noma (HCC) in 2002 reduced the number of adult patients
on the liver transplant waiting list, changed the character-
istics of transplant recipients and increased the number of
patients receiving simultaneous liver–kidney (SLK) trans-
plantation. During this period, the donor age increased,
the retransplantation rates for hepatitis C (HCV) decreased,
and the number of patients receiving grafts from either a
living donor liver transplantation (LDLT) or a donation after
cardiac death (DCD) donor decreased. In this review, we
will summarize the current status of liver transplantation
in the United States using our analysis of the Scientific
Registry of Transplant Recipients (SRTR) data on patients
transplanted between 1999 and 2008. In addition to provid-
ing a general overview of the current state of liver trans-
plantation in the United States, three specific topics are
addressed in detail, liver transplantation for HCV, retrans-
plantation and SLK. We have attempted to avoid topics
that were detailed in the previous 3 years (1–3). The data
is presented as frequency, percentage or mean (±SEM) as
appropriate. Survival rates were adjusted for age, sex, race
and etiology of liver disease unless otherwise mentioned.
The data provided are for patients who received grafts from
deceased donors unless otherwise specified.
Liver Transplant Waiting List
The introduction of the MELD liver allocation system in
February 2002 changed the dynamics of the liver trans-
plant waiting list. As seen in Figure 1, between 2002 and
2008, the number of candidates remaining on the waiting
list at the end of the calendar year decreased by 3.4%. Dur-
ing the same time period, the number of candidates with
hepatitis C decreased marginally (5.9%) and the number
of candidates with HCC increased by 108%.
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Figure 1: Number of candidates on the liver waiting list by
the end of the calendar year.
MELD exception and scores
These scores were assigned to patients with mortality risk
that was not adequately addressed by their MELD/PELD
scores. In general, these groups have included candidates
with HCC or other diagnoses. Candidates with HCC within
the Milan criteria are awarded standard MELD exception
scores with the intent to limit the risk of removal from the
waiting list for cancer progression. Patients outside of the
Milan criteria were awarded MELD exception scores only
if approved by the appropriate Regional Review Board. Ex-
ceptions for indications other than HCC were also awarded
through a Regional Review Board if a candidate’s risk for
death was not felt to be appropriately reflected by their
laboratory MELD score.
As seen in Table 1, the number of candidates remaining
on the waiting list with a MELD exception at the end of
the calendar year increased from 382 in 2002 up to 890
in 2008. The proportion of standard HCC exceptions de-
creased from 69.6% in 2002 down to 44.6% in 2008, but
the number of candidates on the waiting list at the end of
the year with a nonstandard MELD exception for HCC in-
creased considerably from 1.0% in 2002 to 20.6% in 2008.
Between 2002 and 2008, the proportion of candidates on
the waiting list at the end of the calendar year with other
exceptions fluctuated between 29.3% and 41.4%, without
any clear trends (Table 1).
The number of candidates with MELD exceptions remain-
ing on the waiting list at the end of 2008 varied considerably
between Regions with only 20 in Region 10 and up to 229
in Region 5 (Table 2). The proportion of candidates with
a standard HCC MELD exception score ranged between
15.0% (Region 10) to 63.5% (Region 7). For example, for
Region 10, 80% of the candidates with MELD exception
scores on the waiting list at the end of 2008 were for in-
dications other than HCC. In contrast, almost two of three
exceptions for candidates in Region 7 were standard HCC
MELD exceptions. The mean exception scores also ranged
considerably between Regions. Between Regions, stan-
dard HCC exception scores for candidates on the waiting
list at the end of 2008 ranged between 21.4 through 24.2
points and nonstandard (other) HCC exceptions ranged be-
tween 22 through 26.2 points. There was an even greater
range for other exceptions (range of 19.1–28.5 points).
Removal from waiting list
The annual drop-out rates from the waiting list (number of
patients removed for death or for being too sick per 1000
patient-years at risk) remained relatively stable over the
decade as shown in Figure 2. Between 1999 and 2008,
the number of patients alive on the waiting list at any time
during the year ranged between 20 965 in 1999 and 26 695
in 2006. The drop out rate (removals for death or being too
sick per 1000 patient-years at risk) was greatest in 1999 at
186.8 compared to 160.5 in 2008.
Liver Transplant Recipient Characteristics
The number of transplant recipients steadily increased
from 4969 in 2002 to 6363 in 2006, but there was a decline
in 2007 (n = 6228) and in 2008 (n = 6069) (Figure 3). Dur-
ing the same period, the number of transplant recipients
with HCC increased steadily from 999 in 2002 to 1656 in
2008 (Figure 3). The retransplantation rates decreased dur-
ing this period for both HCV positive (from 8% to 5%) and
HCV negative (from 11–12% to 9%) recipients. The age
and race distribution of patients who received deceased
donor liver transplants is shown in Figure 4A, B.
MELD exception rates and scores
The distribution of HCC exception scores among liver
transplant recipients between 2002 and 2008 is shown in
Table 3. In 2002, 71.1% of liver recipients with exception
scores received a standard exception for a T2 tumor, 15.3%
received a T1 standard exception score and only 1.7% re-
ceived an exception score for HCC other than a standard
exception. In contrast, the number of patients transplanted
with a nonstandard exception for HCC increased to 18.2%
in 2008. From 2005, MELD exception scores were not
Table 1: Liver candidates on the waiting list at the end of the year with a MELD exception
2002 2003 2004 2005 2006 2007 2008
N 382 485 490 535 599 755 890
Standard HCC (%) 69.6 57.7 52.9 54.2 53.4 53.4 44.6
Other HCC (%) 1.0 5.4 5.7 5.4 11.5 12.3 20.6
Other exceptions (%) 29.3 36.9 41.4 40.4 35.1 34.3 34.8
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Table 2: MELD exceptions for candidates on the waiting list at
the end of 2008 by Region
Standard HCC Other HCC Other
exception exception exception
Distribution by region (N)
1 (66) 51.5% 25.8% 22.7%
2 (118) 44.9% 11.0% 44.1%
3 (48) 35.4% 2.1% 62.5%
4 (109) 44.0% 16.5% 39.4%
5 (229) 39.3% 39.7% 21.0%
6 (21) 23.8% 19.0% 57.1%
7 (85) 63.5% 5.9% 30.6%
8 (40) 55.0% 2.5% 42.5%
9 (127) 49.6% 24.4% 26.0%
10 (20) 15.0% 5.0% 80.0%
11 (27) 29.6% 3.7% 66.7%
Mean exception score received by region
1 23.8 26.2 26.9
2 22.9 23.8 28.5
3 21.4 – 19.1
4 22.7 22.8 20.5
5 23.7 24.3 24.3
6 23.8 22.0 24.3
7 23.6 24.2 23.1
8 23.3 22.0 22.8
9 24.2 25.7 27.2
10 22.0 22.0 22.8
11 22.4 22.0 21.7
routinely given for T1 tumors, which led to a decrease
in the proportion of liver recipients with a standard T1 ex-
ception in 2008 to only 0.4%. In 2002, 11.9% of the HCC
recipients were transplanted without a MELD exception
score and this increased to 18.8% in 2008.
Loco-regional therapy for HCC
The proportion of liver transplant recipients receiving loco-
regional therapy prior to transplant has increased steadily
from 2003 (37.3%) through 2008 (58.1%; Figure 5A).
Transarterial chemoembolization (TACE) and radio-
frequency ablation (RFA) were the most common
modalities utilized (Figure 5B). Of the patients receiving
pretransplant loco-regional therapy, the proportion re-
ceiving TACE increased from 65.7% in 2003 to 74.4%
in 2008. Details regarding the type of TACE were not
available. In contrast, the proportion of patients receiving
RFA decreased from 38.1% in 2003 down to 32.1% in
2008. Other modalities, including chemical ablation and
cryotherapy were used infrequently throughout all years
from 2003 to 2008.
Waiting time
With the initiation of the MELD system for liver alloca-
tion in February 2002, the emphasis on waiting time had
markedly diminished. As seen in Figure 6, the proportion
of patients transplanted within 30 days of being listed was
relatively steady between 1999 to 2001. While only 23%
were transplanted within a month after listing in 2001,
29.2% were transplanted in 2002 after the introduction
of the MELD score for organ allocation. This proportion of
patients transplanted within 1 month increased to 39% in
2005 and decreased marginally to 36.8% in 2008. In con-
trast, the proportion of liver transplant recipients waiting
for more than 6 months on the waiting list has generally
decreased in the MELD era when compared to those trans-
planted before February 2002.
Considerable variation existed between waiting times for
recipients in different Regions. As noted in Figure 7, only
42.8% of recipients waited 90 days or less in Region 5
compared to 70.9% of liver recipients in Region 3.
Comorbidities and renal insufficiency
The proportion of liver transplant recipients with significant
comorbidities has increased over the decade (Table 4). In
Figure 2: Patients alive on the waiting
list at any time during the year and an-
nual drop out (removal for death or be-
ing too sick) rates from the liver wait-
ing list per 1000 patient-years.
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Figure 3: Comparison of HCC liver recipients to all liver recip-
ients by year of transplant.
1999, 7.8% of recipients were noted to have a body mass
index (BMI) ≥35 kg/m2 (severe or morbid obesity) com-
pared to 11.0% in 2008. In addition, the proportion of liver
recipients with diabetes increased from 14.9% in 1999 up
to 21.5% in 2008. Patients with renal insufficiency (defined
as serum creatinine ≥1.5 mg/dL) increased from 26.1% in
2002 to 32.5% in 2005. This proportion has been relatively
steady since that time with 29.8% of recipients having
renal insufficiency in 2008. The number of patients with
hepatopulmonary syndrome, transplanted with MELD ex-
ception scores, increased from 54 in 2002 to 90 in 2008.
Recipients of DCD grafts
As the supply of organs has failed to meet the demand
of candidates on the waiting list, interest in using DCD
organs increased over the decade. As seen in Table 5,
the number of DCD donors increased and peaked in 2007
at 307 (compared to 23 in 1999). Perhaps as a result of
several reports demonstrating inferior graft survival of DCD
livers when compared to donation following brain death,
this number decreased to 276 in 2008.
Post Liver Transplant Survival and
Predictors of Survival
Liver transplant survival increased over the decade. For
those who received a liver from a deceased donor, the 3-
month, 1-year, 5-year and 10-year unadjusted graft survival
rates were 91.2%, 84.3%, 68.4% and 54.1% respectively,
and unadjusted patient survival rates were 94.3%, 88.4%,
73.8% and 60.0% respectively (Figure 8A). Please note
that for 3-month and 1-year transplantation, only those
transplanted in 2006 and 2007 (GS n = 11 458, PS n =
10 551) were analyzed, while for 5-years and 10-years, only
those transplanted between 2002–2007 (GS n = 32 307,
PS n = 29 604) and 1997–2007 (GS n = 53 673, PS n =
Figure 4: (A) The age distribution of patients who received
deceased donor liver transplants during 1999–2008. (B) The
race distribution of patients who received deceased donor liver
transplants during 1999–2008.
48 827) were analyzed [Table 9.10a]. For patient survival,
only primary liver transplant was considered, and for graft
survival all transplants were analyzed. For LDLT, unadjusted
graft and patient survival at 3-months, 1-year, 5-years and
10-years are shown in Figure 8B; in this analysis, for 3-
months and 1-year transplantation, only those who were
transplanted in 2006 and 2007 (GS n = 537, PS n = 532)
were analyzed, while for 5-years and 10-years, those who
were transplanted between 2002–2007 (GS n = 1854,
PS n = 1821) and 1997–2007 (GS n = 3201, PS n =
3126) were analyzed [Table 9.10b]. Compared to deceased
donors, the outcomes were better for LDLT at 1-year, 5-
years and 10-years (Figure 8A, B).
There has been a trend toward better 1-year adjusted (ad-
justed for age, sex, race and etiology) graft and patient sur-
vival rates during the decade (Figure 9A and 9B). One year
graft survival improved from 79.5% in 1998 to 85.6% in
2007 while patient survival improved from 85.4% in 1998
to 89.4% in 2007. This improvement was seen irrespective
of age, race, sex, etiology, BMI, presence of diabetes and
renal insufficiency. One year adjusted graft survival (68.1%
in 1998 to 86.7% in 2007) and patient survival (78.9% in
1998 to 91.7% in 2007) for those who received grafts from
a living donor also improved over the decade (Figure 9B).
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Table 3: Distribution of HCC exceptions among liver transplant recipients by year of transplant
2002 2003 2004 2005 2006 2007 2008
N 999 1027 1165 1284 1458 1534 1656
Type of exception
T1 (%) 15.3 13.3 5.8 0.6 0.4 0.3 0.4
T2 (%) 71.1 68.5 69.6 68.8 68.2 67.8 62.7
Other (%) 1.7 5.2 8.2 9.8 9.5 13.0 18.2
None (%) 11.9 13.0 16.5 20.8 21.9 18.9 18.8
Recipient factors such as age, race, etiology of liver dis-
ease including HCC, BMI, presence of diabetes, previ-
ous liver transplantation and donor factors such as age
and race had an effect on 1-year patient survival. Hospi-
talized patients and those on mechanical support had a
lower survival [Table 9.10a]. Blood type and sex had no
effect. Data were available for recipient serum sodium and
organ preservation solution between 2005 and 2008; nei-
ther recipient serum sodium (<130 vs. ≥130 mmol/L) nor
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Figure 5: (A) Proportion of HCC liver recipients receiving any
pretransplant loco-regional therapy by year of transplant. (B)
Comparison of different modalities utilized for loco-regional ther-
apy by year of transplant for treated liver recipients.
Figure 6: Distribution of time from listing until transplant
among liver recipients by year of transplant.
[UW] solution Viaspan vs. Custodiol R© histidine-tryptophan-
ketogluterate [HTK]) had an impact on survival. Please note
that over the past 4 years (2005–2008), approximately 27%
of all liver allografts utilized Custodial R© HTK preservation
solution compared to 68% for UW solution (SRTR analysis
2009).
Recipient age
Age remained an important predictor of short and long-
term adjusted graft and patient survival [Tables 9.8a and
9.12a]. In children (aged <18 years), the best survival out-
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Figure 7: Proportion of liver transplant recipients with a wait-
ing time of 90 days or less by Region.
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Table 4: Incidence of comorbidities among liver recipients by year of transplant
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Number of patients 4498 4595 4672 4969 5351 5848 6121 6363 6228 6069
Obesity (BMI ≥ 35 kg/m2; %) 7.8 8.5 8.3 6.9 8.2 8.9 8.3 8.4 9.8 11.0
Diabetes (%) 14.9 15.6 17.8 16.8 18.1 18.9 18.9 21.6 22.0 21.5
Renal insufficiency (Cr ≥ 1.5 mg/dL; %) – – – 26.1 29.1 30.8 32.5 30.2 31.1 29.8
10-years. Five year graft survival ranged between 75.1%
and 78.5% for children, and 10-year survival ranged be-
tween 59.6% and 71.4%. For adults, 1-year graft survival
ranged between 82.0% and 85.6%; 5-year survival ranged
between 61.5% and 69.9% and 10-year survival was be-
tween 41.1% and 56.0%. The worst 5-year (61.5%) and
10-year (41.1%) graft survival was seen in those who were
aged ≥65 years and older. The impact of age on graft and
patient survival was also observed for adults who received
LDLT, but the overall outcomes were better for those who
received LDLT [Tables 9.8b and 9.12b].
Sex and race
Among the liver transplant recipients, male:female ratio
was 2:1. Sex did not have any impact on survival. Race
continues to have a major impact on long-term graft and
patient survival [Tables 9.8a and 9.12a]. African Americans
had the worst graft outcomes at 5-years (60.0%) and 10-
years (45.4%) whereas Asians had the best outcomes at 1-
year (88.1%), 5-years (73.7%) and 10-years (63.1%). These
differences were also observed for LDLT [Tables 9.8b and
9.12b].
Etiology of liver disease
Etiology remained a major predictor of adjusted graft sur-
vival [Table 9.8a]. Whereas cholestatic liver diseases, biliary
atresia and metabolic diseases had the best outcomes at
all time intervals, malignant diseases had the worst out-
comes at 5-years (63.5%) and 10-years (45.9%). Similar
observations were noted for those who received LDLT [Ta-
bles 9.8b]. For patients who were transplanted between
2002 and 2007 with HCC, 5-year unadjusted graft survival
was better for T1 stage (n = 357; 71.1%) compared to
T2 stage (n = 4934; 65.7%) [Table 9.10a]. The survival of
patients who received loco-regional therapy for HCC ver-
Table 5: Liver transplants from DCD donors by year of transplant
Total donors DCD DCD donors
Year of transplant N N of total (%)
1999 4498 23 0.5
2000 4595 39 0.8
2001 4672 69 1.5
2002 4969 79 1.6
2003 5351 111 2.1
2004 5848 185 3.2
2005 6121 271 4.4
2006 6363 289 4.5
2007 6228 307 4.9
2008 6069 276 4.5
sus no therapy prior to liver transplantation is shown in
Table 6.
Hospitalization status
There was a decrease in the number of hospitalized pa-
tients receiving transplants during this period. This de-
crease was seen both for HCV positive (31–24%) and HCV
negative (42-34%) recipients. A similar trend was seen for
both HCV positive (19–7%) and HCV negative (28–16%) pa-
tients transplanted from the intensive care unit. The rates
for patients on mechanical support also declined for both
HCV positive (7% to 3–4%) and HCV negative (16–9%)
groups (SRTR analysis 2009). Patients who were hospital-
ized (1-year unadjusted graft survival 82.2% vs. 86.8%) had
approximately 4% lower survival than those who were not
hospitalized. The impact was higher for those who were
in the intensive care unit (1-year unadjusted graft survival
73.3% vs. 86.8% for nonhospitalized) or on mechanical
support at the time of transplant (67.5% vs. 85.5% for
those who were not on mechanical support) [Table 9.10a].
Transplantation by state
Data were analyzed according to the state instead of the
center for the sake of confidentiality. Highest numbers
of transplants were performed in California followed by
Florida, New York, Texas and Pennsylvania. Adjusted graft
and patient survival showed differences at all time intervals
among the states [Tables 9.8a and 9.12a]. One year graft
survival ranged between 73.1% (Maryland) and 96.2%
(Arkansas). Yearly center volume had only minimal impact
on outcomes, but there was a trend toward lower unad-
justed graft survival among centers that transplanted less
than 10 patients per year, or more than 57 patients per year
[Table 9.10a].
MELD and PELD scores
The MELD and PELD score at the time of transplantation
had a significant effect on survival. Recipients with MELD
scores between 11 and 20 had the best unadjusted graft
and patient survival rates at 3-months, 1-year and 5-years,
with the worst outcomes in those with MELD scores >30.
Similarly, those with PELD scores >30 had the worst out-
comes [Tables 9.10a and 9.14a].
Donor age
Best outcomes were observed for donors aged between
1 and 34 years, and worst outcomes were observed for
donors who were aged <1-year or aged ≥65 years. As
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Source:  2009 OPTN/SRTR Annual Report, Tables 9.10b and 9.14b.
B
Figure 8: (A) Unadjusted 3-month, 1-year, 5-year and 10-year graft and patient survival after deceased donor liver transplantation.
Please note that graft survival is for all transplants and patient survival is only for primary transplants. (B) Unadjusted 3-month, 1-year,
5-year and 10-year patient survival after living donor liver transplantation. Please note that graft survival is for all transplants and patient
survival is only for primary transplants.
donor age increased, there was a trend towards lower 5-
year and 10-year unadjusted graft survival [Tables 9.10a].
Cold ischemia time
Few patients received grafts with cold ischemia time (CIT)
>15 h. Between 2006 and 2007, 948 grafts had CIT be-
tween 11 and 15 h, 83 had CIT between 16 and 20 h and
71 had CIT >21 h; 1-year unadjusted graft survival was
80.1%, 77.1% and 81.7% respectively for these groups
[Table 9.10a]. In contrast 1-year unadjusted graft survival
was 87.9% when CIT was between 0 and 5 h (n = 3287),
and 83.7% for CIT between 6 and 10 h (n = 6042) [Table
9.10a]. For both HCV and non-HCV recipients, CIT became
progressively shorter over time. The percentage of trans-
plants with CIT less than 6 h increased from 16% to 34%
by 2008 for HCV patients, and nearly identical trends and
rates for CIT were seen in HCV negative recipients.
Liver Transplantation for Hepatitis C
HCV is the most common indication for liver transplanta-
tion in the United States. From 1999 through 2007, the
number of recipients with HCV increased to a peak of
2481 in 2006 representing more than one third (37–41%)
of all recipients. In the second half of the decade, the
rates remained relatively stable at around 2400 transplants
annually. Unless otherwise stated, the following analysis
includes only deceased donor transplantation.
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Figure 9: (A) 1-year adjusted (adjusted for age, sex, race and
etiology) graft and patient survival rates for deceased donor
liver transplantation by year of transplantation. (B) 1-year ad-
justed (adjusted for age, sex, race and etiology) living donor graft
and patient survival by year of transplantation.
Recipient characteristics
The age of patients transplanted for HCV increased be-
tween 1999 and 2008. The most prominent shift occurred
in the 50–64 years of age group, which increased from
37% (n = 667) in 1999 to 74% (1746) in 2008. The num-
ber of transplants for HCV patients aged ≥65 years, how-
ever, remained small during this period (100–160 per year
or 6–7%) and similarly, only a small number (<50 per
year) of transplants were performed in patients aged ≤35
years. Most transplants for HCV were for men (70–80%)
and in contrast, 40–45% of HCV negative recipients were
women. During this period, the proportion of white recip-
ients with HCV decreased (from 77% in 1999 to 70% in
2008) while the proportion of African American recipients
increased (from 7–8% to 10–11%). This increase was sub-
stantial as it represented a doubling in the absolute num-
bers of transplants performed in African Americans, from
125 in 1999 to 249 in 2008. The rates for Hispanic/Latinos
(12–15%) and Asians (3–4%) remained stable through-
out the decade. In HCV negative recipients, a similar de-
crease in the proportion of white recipients was seen dur-
ing the decade (from 75% to 69%). The redistribution,
however, occurred mostly in the Hispanic/Latinos group,
where the rates increased from 9% to 14%. With rates
hovering at around 10% steadily throughout the decade,
the rates for HCV negative African Americans remained
stable.
There was a decrease in transplantation for hospitalized
patients, and those in the intensive care unit or on mechan-
ical support as discussed earlier. Rates of transplantation
for low MELD scores decreased steadily since the insti-
tution of MELD for both HCV positive and HCV negative
patients. Among HCV recipients, transplantation rates de-
creased from 3–4% to 1% for patients with MELD scores
of 6–10, and for those with MELD scores of 11–14 rates
decreased from 8% to 2%. The rates remained steady
for those with MELD scores 15–20 (17–20%) and MELD
scores >30 (14–19%), but increased from 40% to 61% in
those with MELD scores of 21–30. The distributions and
trends for HCV negative patients were similar to that of
HCV positive patients except that there were about 10%
fewer recipients in the 21–30 MELD group and somewhat
more recipients at the extremes (in the MELD <14 and
>30 groups).
Partial or split liver transplants were done infrequently for
HCV positive recipients (n ≤40 transplants, <2% per year).
In contrast, partial and split livers were used more fre-
quently in HCV negative patients (n = 150–200, 5–6% per
year). The number of LDLT for HCV positive recipients de-
creased from 176 in 2001 to 64 in 2008. Although the
number of LDLT decreased in HCV negative recipients also
during this period, the decrease was relatively less (348 in
2001 to 185 in 2008).
Table 6: Unadjusted patient survival at 1 year, 3 years, and 5 years by ablation therapy
1-Year 3-Years 5-Years
Ablation therapy N % Std. Err. N % Std. Err. N % Std. Err.
No ablation 1032 89.1% 1.0% 2005 75.3% 1.1% 2398 67.4% 1.4%
Any ablation therapy 1301 88.9% 0.9% 2277 76.6% 1.1% 2507 69.9% 1.5%
Chemo ablation 932 88.6% 1.0% 1563 76.8% 1.3% 1715 69.7% 1.9%
Radio ablation 430 89.5% 1.5% 805 77.4% 1.7% 891 72.3% 2.4%
Cryo ablation 11 81.8% 11.6% 14 78.6% 11.0% 17 57.4% 18.3%
Chemical ablation 56 92.9% 3.4% 110 74.5% 4.9% 121 63.4% 6.5%
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Figure 10: Patient survival in HCV
patients compared to HCV negative
patients.
Survival
Patient survival was lower in HCV patients compared to
non-HCV patients (Figure 10). One-year adjusted patient
survival improved marginally for HCV positive recipients
(85–88%) during this decade. Additionally, 1-year survival
of HCV patients aged >64 years showed a relatively strong
improvement (from 78% to 89%). Donor age was an impor-
tant risk factor, demonstrating significantly worse 1-year
patient survival in recipients of donors aged >34 years.
There was not much change in this effect over the decade,
except perhaps a suggestion of improving results over time
for recipients of donors aged >64. Among LDLT recipients,
there was a significant difference in unadjusted 3-year and
5-year patient survival between HCV positive (82%, 75%)
and HCV negative (86%, 81%, p < 0.0001) recipients. One
year patient survival after retransplantation did not change
much over the decade for recipients with HCV; it oscillated
around 70%. In contrast, outcomes for retransplantation in
HCV negative recipients steadily improved during this era,
increasing from 64% to 81%.
Independent Predictors of Survival Among
HCV Recipients
Recipient factors
In this analysis, we performed a multivariate analysis of
patient survival using all variables that were found to be
statistically significant in the univariate model. Recipient
age was found to be an important risk factor for two
recipient age groups, the 35–49 year old cohort, where
the risk of death at 1-year was 13% lower (relative risk
[RR] = 0.87, p = 0.0013) than that of patients in the 50–
64 year age group (the reference group), and for the over
65 year age group, where the risk of death at 1-year was
20% greater than that of the reference group (RR = 1.20,
p = 0.01). Interestingly, female recipients with HCV were
at significantly greater risk of death: 15% greater within
1-year, 14% greater at 3-years and 14% greater at 5-years
(all p < 0.01). The presence of diabetes (RR = 1.2 for all
three time points, p ≤ 0.0003), being on mechanical sup-
port (RR = 2.1 for death at 1-year, p < 0.0001), a history
of previous abdominal surgery (RR = 1.1 at 1 year, p =
0.007), a previous transplant other than a liver transplant
(RR = 3.7 at 1-year, p < 0.0001), a history of a previous
malignancy (RR = 1.1 at 3-years and 1.2 at 5-years, p <
0.01) and a specific diagnosis of HCC (RR = 1.2 at 1-year,
3-years and 5-years, p < 0.008) were all independent pre-
dictors of mortality. Interestingly, a history of portal vein
thrombosis did not appear to be a significant risk factor at
1-year posttransplantation (RR = 1.2, p = 0.08) in the HCV
positive cohort unlike HCV negative recipients (RR = 1.7 at
1-year, p < 0.0001). Similarly, in contrast to the HCV nega-
tive population, dialysis within the week prior to transplant
was not a statistically significant risk factor. Notably, recip-
ients with private insurance were at lower risk of death at
1-year (RR = 0.89, p = 0.006).
Donor factors
Donor sex was not a risk factor, but donor age was an
important risk factor for death after transplantation in the
HCV positive transplant population (Table 7). For recipients
of donors aged >34 years, the risk of death was signifi-
cantly greater than that of recipients of livers from donors
aged 18–34 years (the reference group). Specifically, the
risk was 16% higher for liver recipients from donors aged
35–49 years, 45% higher for liver donors aged 50–64 years
and 84% higher when the donor was aged >64 years (all
p < 0.006). The deleterious effect of advanced donor age
increased over the time from transplantation, such that
there was a 20% increased risk of death at 5-years for re-
cipients of donors in the 35–49 year old donor age group, a
57% increased risk in the 50–64 year old donor age group
and a 114% increased risk in the over 64 year old donor
age group. DCD grafts significantly increased the risk for
death and graft loss, furthermore, the risk was similar for
HCV positive (RR = 1.6 for patient survival at 1-year, p <
0.0001) and HCV negative (RR = 1.5, p = 0.0002) recipi-
ents. The effect of CIT was significant and similar in HCV
positive and negative recipients.
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Table 7: The impact of donor age on patient survival in recipients with HCV
1-year 3-year 5-year
Donor age RR CI p-Value RR CI p-Value RR CI p-Value
<12 years 0.69 0.46–1.04 0.078 0.66 0.48–0.92 0.015 0.68 0.50–0.92 0.012
12–17 years 0.92 0.77–1.10 0.36 0.92 0.80–1.06 0.23 0.93 0.82–1.05 0.25
35–49 years 1.16 1.05–1.29 0.0058 1.19 1.09–1.29 <0.0001 1.20 1.12–1.30 <0.0001
50–64 years 1.45 1.30–1.61 <0.0001 1.50 1.38–1.63 <0.0001 1.57 1.45–1.69 <0.0001
>65 years 1.84 1.60–2.11 <0.0001 2.01 1.80–2.23 <0.0001 2.14 1.94–2.35 <0.0001
Race and donor–recipient race matching
Both recipient and donor race were important predictors
of survival. When compared to white recipients (the refer-
ence group), the RR was 1.4 for African American recipi-
ents (p < 0.0001), 0.84 for Hispanic/Latino recipients (p <
0.0001) and 0.85 for Asian recipients (p = 0.04). Donor race
also was a risk factor for poor survival; when compared to
white donors (reference group), the RR was 1.08 for His-
panic/Latino donors (p = 0.05), 1.18 for Asian donors (p =
0.04) and 0.93 for African American donors (p = 0.06).
An intriguing observation was the impact of donor–
recipient mismatching on survival, especially the survival
benefit among African American HCV positive recipients
when the donor was also African American (Table 8). Un-
adjusted 5-year patient survival was better among HCV
positive African American recipients when the donor was
also African American when compared to African Amer-
ican recipients who received a liver from a white donor
(72.8% vs. 56.3%). In a multivariate analysis of 5-year pa-
tient survival, the RR by donor–recipient race matching for
HCV positive African American recipients was 1.5 for those
with a white donor (compared to the reference group of
white recipients of white donors), 1.4 for those with a His-
panic/Latino donor and 1.8 for those with an Asian donor
(all p values < 0.006). The interaction of recipient and donor
race was evident even at 1-year (RR = 1.2 for African Amer-
ican recipients of a liver from a white donor, p = 0.005).
Similarly, white HCV recipients had lower survival when
the donor was Asian (Table 8). For white recipients, patient
mortality at 1, 3 and 5 years was significantly higher when
the donor was Asian (RR = 1.3, 1.3, 1.3, all p < 0.10).
The risk also increased for white recipients (RR = 1.2) at
3 and 5 years (but not at 1 year) when the donor was
Hispanic (p < 0.01). For Hispanic/Latino recipients, the 5-
year unadjusted patient survival was lower when the donor
was Asian and this was true for both HCV positive (66.8%
vs. 71.0–77.7% for other donor races) and HCV negative
(68.9% vs. 79.0–82.3% for other races) Hispanic/Latino re-
cipients. It is important to note that the number of Asian
recipients was relatively small for this analysis (for 5-years,
there were 269 Asian donors for HCV positive recipients
and 297 for HCV negative recipients), and therefore, the
interaction with Asian donors should be interpreted with
caution.
Retransplantation
The debate on retransplantation as a measure of organ uti-
lization and cost has only heightened in this age of increas-
ing organ shortage. The difference between patient and
graft survival curves represents the utilization of retrans-
plantation for failed life-saving allografts. This section pro-
vides an overview and analysis of the patterns and causes
Table 8: Unadjusted patient survival by recipient and donor race in HCV positive and negative recipients
HCV negative HCV positive
Recipient/donor race 1-year 3-year 5-year 1-year 3-year 5-year
White/White 88.8 81.8 77.8 88.3 76.7 70.1
White/African American 88.0 80.2 75.0 88.1 77.0 70.4
White/Hispanic 86.0 79.9 75.3 84.8 74.0 63.3
White/Asian 91.8 80.0 73.7 72.0 67.9 57.2
African American/White 91.0 83.5 77.0 82.6 65.9 56.3
African American/African American 87.0 80.8 73.8 86.0 78.6 72.8
African American/Hispanic 87.8 76.3 67.7 90.9 62.5 60.5
African American/Asian 94.4 69.0 60.2 75.0 57.3 51.4
Hispanic/White 89.3 85.1 79.2 90.6 78.6 71.3
Hispanic/African American 89.0 82.1 82.3 88.0 78.2 77.7
Hispanic/Hispanic 91.0 81.2 79.0 88.3 78.5 71.0
Hispanic/Asian 83.3 66.4 68.9 72.2 62.2 66.8
Asian/White 92.8 85.0 82.0 90.5 79.2 73.4
Asian/African American 95.3 82.3 78.1 85.0 81.6 73.1
Asian/Hispanic 93.7 80.9 78.8 74.2 75.7 62.1
Asian/Asian 91.2 86.8 81.0 81.8 66.5 77.8
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Figure 11: Donor risk index for livers used for primary liver
transplant (1999–2008).
for liver retransplantation over the past 10 years, and seeks
to further understand the factors that influence the need
for retransplantation. Factors that impact the need for re-
transplantation are assessed at the donor, recipient and
program level. Outcomes, including patient and graft sur-
vival, as well as utility of transplantation are also analyzed.
Retransplantation trends by donor characteristics
The quality of a donor in terms of the risk for graft loss
can be accurately characterized using the donor risk in-
dex (DRI), an algorithm derived from a comprehensive risk
analysis of the SRTR database. As shown in Figure 11, the
DRI profile of livers used in primary liver transplantation
changed during the period from 1999 to 2008, with a de-
crease in the percentage of donors with DRI <1.3 (17%
decrease) and a corresponding increase in the percentage
of donors with DRI >1.8 (36% increase). The risk for re-
transplantation based on the DRI of the primary liver is
shown in Figure 12, where a stepwise increase in the risk
for retransplantation can be seen for each category of in-
creasing DRI during all years (1999–2008). Nevertheless,
over this period, the risk for retransplantation following pri-
mary liver transplantation decreased from 9.6% to 7.6%
and this was particularly true for the higher DRI livers (DRI
1.5–1.8 and DRI >1.8). In contrast to the increasing DRI of
livers used in primary liver transplantation, the DRI for liv-
ers used for retransplantation decreased over time with an
increase in the percentage of donors with DRI <1.3 (18%
increase) and a corresponding decrease in the percentage
of donors with DRI >1.8 (36% decrease) (Figure 13). Anal-
ysis of the impact of the serum sodium quintiles in the
donor population analyzed during this period did not show
any correlation between higher levels of serum sodium
with the risk for retransplantation. On the other hand, a
well-acknowledged component of DRI is whether the liver
was from a DCD. As shown in Figure 14, while the utiliza-
tion of DCD liver for primary liver transplant increased from
1999 to 2007, the retransplantation rates after DCD did not
change in recent years. Compared to donation after brain
death (DBD), the retransplantation rate was 54% higher
with DCD liver (7.1% vs. 13.0%). Predictably, use of DCD
was lower among retransplanted patients (1.1% vs. 4.8%)
than primary transplants.
Retransplantation trends by recipient characteristics
For the purposes of this overview of retransplantation, we
have defined utility of liver for transplantation as the ratio
of primary liver transplants to liver retransplantation and do
not take into consideration life-years saved (4). As seen in
Figure 15, retransplantation has declined over the last 10
years, as noted by the increase in the ratio of primary liver
transplants to retransplants being performed. In the first
5 years (1999–2003), 1 of every 10.4 grafts was utilized
for retransplantation, whereas in the latter 5 years (2004–
2008), only 1 of every 12 grafts was utilized for retrans-
plantation (an overall improvement in utility of 15%). This
was particularly evident in certain age groups (Figure 15).
In the group of recipients aged 1–5 years, utilization im-
proved 60%, from 1 of 6.0 grafts utilized for retransplan-
tation from 1999–2003 to 1 of 9.6 grafts from 2004–2008.
Similarly in the <1 year age group, utility improved from
1 in 10.5 grafts for retransplants to 1 in 15.2 grafts dur-
ing the latter 5 years (48% improvement) during the same
Figure 12: Retransplantation rates
based on DRI for primary liver trans-
plants.
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Figure 13: Donor risk index for livers used for retransplanta-
tion (1999–2008).
time periods. Improvements were seen in all age groups,
with the 18 to 34 year age group having the lowest degree
of improvement, from 1 in 5.4 grafts used for retransplan-
tation from 1999 to 2003 to 1 in 5.8 grafts from 2004 to
2008 (an increase of 7% utility). Over the past 10 years the
highest utility of liver allograft use in primary liver trans-
plantation was in the oldest and youngest age groups (1
in 21.7 grafts utilized for retransplantation in the age group
>65 years and 1 in 12.6 grafts for the age group <1 year),
compared to the lowest utility (highest retransplantation
rates) in the groups aged 6–11, 18–34 and 12–17 years
(Table 9).
The race of the recipient was also associated with differ-
ential rates for retransplantation (Table 9). Over the past
10 years the highest rate of retransplantation was seen
in African American recipients with a ratio of primary liver
transplants to liver retransplants of 7.8 to 1. The highest
utility of liver allograft use was seen in Asian recipients
with 1 retransplant for every 15.1 liver allografts used. In
the first 5 years compared to the second half of the anal-
ysis period, the rates increased for all groups except for
the recipients designated as ‘Other/Multi-race’ where uti-
lization actually decreased from 1 in 10.6 grafts utilized for
retransplantation to 1 in 8.9 grafts (a decrease of 16% util-
ity). The greatest increase in the utilization of liver allograft
was seen in Asian designated recipients with an increase
in utility from 1 in 11.3 grafts for retransplants in the first
Figure 14: DCD utilization and impact on retransplantation
from 1999 to 2008.
Figure 15: Ratio of primary liver transplants to liver retrans-
plants by recipient age (1999–2008).
5 year period to 1 in 19.3 grafts during the latter 5 years
(70% improvement).
Although the proportion of retransplants utilized by sex
(37.4% female/62.6% male) appeared similar to the pro-
portion of males and females undergoing primary trans-
plantation (34.9% female/65.1% male) over the 10 year
period, females had a slightly higher retransplant rate com-
pared to males, with 1 liver in every 10.5 utilized for re-
transplantation in females, compared to 1 in 11.6 livers uti-
lized for males (12% less utility when transplanting female
recipients compared to male recipients) (SRTR analysis
2009).
Utilizing the diagnosis designation codes employed by the
Organ Procurement and Transplantation Network, the re-
transplant rate by diagnosis was also notable for a wide
range of utility over the 10-year period (Table 9). Aside
from transplant recipients designated as ‘other’, where the
retransplant rate was 1 in 3.3 grafts, the lowest utility of
livers transplanted was for those with acute hepatic necro-
sis, where 1 in 7.2 grafts was used for retransplantation;
only 1 in 41.1 grafts for malignant neoplasms was utilized
for retransplantation.
The United Network for Organ Sharing Region where the
primary liver transplant was performed was also associated
with differential rates of retransplantation with an almost
3-fold difference in the utilization of liver retransplantation
(Table 9). Over the past 10 years the highest rate of retrans-
plantation was seen in recipients transplanted in Region 7
with a ratio of primary liver transplants to liver retransplants
of 7.3:1. In contrast, the highest utility of liver allograft use
was seen in Region 6 recipients with 1 retransplant for
every 21.4 liver allografts used.
Timing and indications for liver retransplantation
The majority of liver retransplants were for first re-
transplants. Retransplantation for the second or greater
remained constant throughout the 10-year period, with
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Table 9: Ratio of primary liver transplants to liver retransplants from 1999 to 2008
Age Race Diagnosis Region
Age groups UR Race UR Primary diagnosis UR Region UR
Overall 10.2 Overall 10.2 Overall 10.2 Overall 10.2
<1 year 11.6 White 10.3 Noncholestatic 16.6 Region 1 13.2
1–5 6.5 African American 7.8 Cholestatic 7.1 Region 2 9.6
6–11 4.2 Other/Multi-Race 8.5 AHN 6.2 Region 3 9.7
12–17 5.6 Asian 14.1 Biliary atresia 7.0 Region 4 18.0
18–34 4.6 Hispanic/Latino 11.1 Metabolic 12.3 Region 5 10.7
35–49 9.2 Malignant 40.1 Region 6 20.4
50–64 12.5 Others 2.3 Region 7 7.3




UR, Utility ratio is the ratio of primary liver transplants to liver retransplantation; AHN, acute hepatic necrosis.
approximately 10% of all allografts utilized for retransplan-
tation being used for second or rarely third retransplants.
The timing of retransplantation was quite broad. The mean
time to retransplantation was 962 ± 1453 days, while the
median time to retransplantation was 222 days. Only 25%
of retransplants fell into the immediate posttransplant pe-
riod of 14 days. The quartile with the longest time to re-
transplant received their retransplant more than 3.5 years
following their prior transplant.
The indications for retransplantation are listed in Table 10.
As was noted in a previous SRTR analysis (5), the most
common cause for retransplantation in the first 14 days
after transplantation was primary nonfunction, followed by
vascular thrombosis. After the mid-point, the most com-
mon causes for retransplantation were: recurrent diseases,
chronic rejection and biliary complications. As the number
of patients whose primary liver transplant was for diseases
known to recur, (e.g. primary biliary cirrhosis, primary scle-
rosing cholangitis, nonalcoholic steatohepatitis, Hepatitis
C, Hepatitis B, autoimmune hepatitis), have continued to
grow, it is not surprising to see the shift in retransplanta-
tion for those patients well into the third and fourth quartile
periods.
Outcomes of retransplantation
Survival outcomes following retransplantation were infe-
rior to primary liver transplantation. Figure 16 demon-
strates the differences between the 1-year patient sur-
vivals between primary transplants and retransplants. Over
the 10-year period, however, while 1-year primary liver
transplant patient survival improved by 4.1%, the corre-
sponding survival for first retransplant recipients increased
by 13.0%. As has been reported before, the timing from
primary liver transplant to retransplantation may play an
important role in determining survival outcome (6). Over
the 10-year period from 1998 to 2007, the 1-year patient
survival for first retransplants in the lowest follow-up quar-
tile was 65.8%; for the second quartile, it was 68.1%;
for the third quartile, it was 70.0% and the highest was
in the fourth quartile at 77.3%. As seen in Figure 17,
the trend in the second half of the analytic period was
Table 10: Causes of graft failure in liver retransplant recipients by time from first transplant to retransplant (n = 3969 recipients with a
first retransplant between 1999 and 2008)
Quartiles/time from primary transplant to retransplant
Quartile 1 Quartile 2 Quartile 3 Quartile 4
0–14 days 15–222 days 223–1307 days >1308 days
Cause of graft failure1 N % N % N % N %
Primary graft failure 653 64.1 204 21.1 100 10.1 88 8.9
Vascular thrombosis 283 27.8 318 32.9 114 11.5 53 5.3
Biliary tract complication 14 1.4 142 14.7 146 14.7 53 5.3
Hepatitis: de novo 0 0.0 1 0.1 10 1.0 10 1.0
Hepatitis: recurrent 5 0.5 51 5.3 243 24.5 200 20.2
Recurrent disease 1 0.1 12 1.2 103 10.4 175 17.6
Acute rejection 42 4.1 67 6.9 50 5.0 22 2.2
Chronic rejection 1 0.1 34 3.5 183 18.5 204 20.6
Infection 15 1.5 83 8.6 51 5.1 25 2.5
Patient noncompliance 0 0.0 0 0.0 8 0.8 6 0.6
Missing 126 12.4 265 27.4 277 27.9 367 37.0
1Cause of graft failure of the primary transplant. Some patients may have multiple causes of graft failure.
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Figure 16: One-year patient survival for primary and retrans-
plantation by year of transplantation.
notable for a shift away from early retransplantation to
late retransplantation with a corresponding increase in
survival.
Several single center reports have indicated that the over-
all incidence of retransplantation has fallen over time (7).
Reduction in graft loss due to acute rejection, technical
complications and patient death may have been behind
this trend. Nevertheless, with an increasing DRI, meeting
the challenge of improving early graft function in the face
of increasing donor age, and the use of DCD livers and
fatty livers, efforts must focus on reducing early retrans-
plantation. Reducing the impact of recurrent disease, in
particular HCV, remains a major challenge in reducing the
need for late retransplantation. In addition, as indicated in
this analysis, there are also regional practices that appear
to influence the risk of retransplantation that have not been
clarified.
SLK Transplantation
The number of SLK transplants has increased from 100
in 1999 to a peak of 445 in 2007. The upward trend
was broken in 2008 when there was a decrease to 379
combined liver–kidney transplants performed, which rep-
resented 6.2% of all liver transplants performed. As ex-
pected, MELD score SLK patients transplanted in the past
decade was higher (mean 29.2, range 25.4–32.1) than
those who were transplanted for liver only (mean 23.6,
range 21.7–25.3). The difference in the mean MELD score
between these two groups varied between Regions (range
4.2 [in Regions 6, 8, 10] to 6.0 [in Region 7]). Regions 1
(11.9%), 7 (11.4%) and 5 (8.2%) had a relatively higher per-
centage of SLK. In other centers, the percentage of SLK
ranged between 3.3% (Region 6 and 5) and 6% (Region
4). While the total number of liver transplants increased
by 35% over the last 10 years (from 4498 to 6069), the
number of SLK transplants increased by over 279% (from
100 to 379) (Table 11). Reasons for this increase in SLK
over the last decade were likely multifactorial, however,
two significant factors may have played an important role.
First, evidence of increased postoperative mortality with
liver transplant alone in patients with renal insufficiency
shaped clinical practice patterns in many transplant cen-
ters to consider SLK in patients with renal insufficiency
and cirrhosis. This practice was particularly prevalent in
patients with acute renal failure due to hepatorenal syn-
drome, especially when those patients required hemodial-
ysis. The second factor was the introduction of the MELD
system for liver allocation in 2002. Creatinine was included
as a major determinant of the score and thus renal insuf-
ficiency prioritized patients for liver allocation. Selection
criteria for SLK have evolved over the last 5 years as our
understanding of the profile of patients likely to have renal
recovery after transplantation began to evolve. In addition,
in 2006, a consensus conference on SLK was held in the
United States, which helped to define the recipients in
need of SLK. Specifically, the conference conclusions rec-
ommended SLK for patients with chronic renal failure and
creatinine clearance <30 mL/min. In patients with acute re-
nal failure, the need for dialysis >6 weeks was believed to
merit SLK consideration (8,9). Perhaps because of these
recommendations, the annual increase in the number of
SLK transplants finally declined in 2008, but it remains to
be seen whether this decline will continue in the next few
years.
Cause of liver disease
The primary diagnosis of liver disease in over 70% of
patients undergoing SLK was noncholestatic cirrhosis
(Table 11). Commonly, patients referred for renal
Figure 17: Number and patient sur-
vival outcome following retransplan-
tation by quartile —1998 to 2007.
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Table 11: SLK transplantation by etiology of liver disease
Year of transplant
Primary liver diagnosis 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Total number (%) 100 135 135 210 247 279 340 400 445 379
Non-cholestatic cirrhosis 51 (51) 87 (64.4) 89 (65.9) 151 (71.9) 173 (70.0) 206 (73.8) 246 (72.4) 286 (71.5) 298 (67.0) 273 (72.0)
Cholestatic liver disease 13 (13) 7 (5.2) 8 (5.9) 12 (5.7) 15 (6.1) 17 (6.1) 18 (5.3) 31 (7.8) 22 (4.9) 23 (6.1)
Acute hepatic necrosis 5 (5) 7 (5.2) 10 (7.4) 6 (2.9) 14 (5.7) 14 (5.0) 11 (3.2) 15 (3.8) 23 (5.2) 6 (1.6)
Biliary atresia – 2 (1.5) – 1 (0.5) 2 (0.8) 3 (1.1) 3 (0.9) – 2 (0.4) 1 (0.3)
Metabolic diseases 11 (11) 9 (6.7) 8 (5.9) 11 (5.2) 6 (2.4) 12 (4.3) 12 (3.5) 13 (3.3) 21 (4.7) 10 (2.6)
Malignant neoplasms – 2 (1.5) 1 (0.7) 4 (1.9) 6 (2.4) 5 (1.8) 11 (3.2) 12 (3.0) 20 (4.5) 16 (4.2)
Others 20 (20) 21 (15.6) 19 (14.1) 25 (11.9) 31 (12.6) 22 (7.9) 39 (11.5) 43 (10.8) 59 (13.3) 50 (13.2)
transplantation with chronic HCV are deemed poor can-
didates for renal transplant alone and are then referred
for SLK consideration. Even without advanced liver dis-
ease, the contribution to the MELD score from creatinine
alone would enable these wait-listed candidates to gain
priority on the allocation list for a SLK. This circumstance,
however, does not account for all differences in the inci-
dence of SLK in patients with noncholestatic cirrhosis, as
the total number of transplants received by patients with
noncholestatic cirrhosis in 2008 was approximately 56%,
while 72% of SLK were performed in patients with non-
cholestatic cirrhosis [Table 9.4a]. Thus, there is a greater
requirement for SLK in patients with noncholestatic liver
disease than would be predicted by the requirement for
liver transplant alone. Certainly, some glomerular diseases
and diabetes are known to have a higher association with
HCV than with other primary liver diagnoses. For essen-
tially all primary liver diagnoses, the peak number of SLK
occurred between 2002 and 2006. For some diagnoses
such as biliary atresia, the number of SLK transplants has
remained minuscule over the last 10 years and represents
a smaller proportion of SLK than the percentage of pa-
tients receiving liver transplant alone for this indication.
For cholestatic liver disease, however, the number of SLK
transplants has remained consistently between 5% and
6% of total liver transplants performed for that indication
(Table 11). For patients with metabolic disease, the number
of SLK transplants has been comparable peaking at approx-
imately 5% of all SLK. In 2008, 18.4% of patients who did
not receive SLK transplantation had malignant disease, and
only 4.2% of patients who received SLK had malignant dis-
ease. The smaller proportion of SLK in this group is likely
influenced by the MELD exception points awarded to tu-
mor patients which allowed access to liver transplant at an
earlier physiologic stage in their underlying liver disease.
Acute hepatic necrosis represented the indication with the
greatest decline in SLK transplants. Most likely, this is a
result of centers rethinking the indications for SLK in the
setting of acute renal failure when patients are not on dial-
ysis or on dialysis for less than 60 days. In 2007, 23 SLK
transplants were performed in patients with acute hepatic
necrosis representing 5.2% of total SLK, while in 2008 only
6 SLKs (1.6%) were performed in patients with acute hep-
atic necrosis. The influence of current data demonstrating
the likely return of renal function when there is acute renal
failure with limited dialysis exposure has likely influenced
the precipitous decline in SLK in acute hepatic necrosis.
Most of these patients are transplanted within 7 days of
listing and thus fall into the category of limited or no dialysis
with acute renal failure.
Table 12: SLK transplantation-–primary kidney diagnosis
Year of transplant
Primary kidney diagnosis 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Total number (%) 100 135 135 210 247 279 340 400 445 379
Glomerular diseases 12 (12.0) 23 (17.0) 16 (11.9) 24 (11.4) 40 (16.2) 41 (14.7) 54 (15.9) 57 (14.3) 30 (6.7) 41 (10.8)
Diabetes 11 (11.0) 16 (11.9) 19 (14.1) 25 (11.9) 39 (15.8) 38 (13.6) 48 (14.1) 73 (18.3) 74 (16.6) 67 (17.7)
Hypertensive
nephrosclerosis
3 (3.0) 9 (6.7) 8 (5.9) 8 (3.8) 15 (6.1) 18 (6.5) 33 (9.7) 27 (6.8) 41 (9.2) 33 (8.7)
Polycystic kidneys 16 (16.0) 7 (5.2) 15 (11.1) 18 (8.6) 16 (6.5) 19 (6.8) 15 (4.4) 19 (4.8) 21 (4.7) 23 (6.1)
Tubular and interstitial
diseases
22 (22.0) 21 (15.6) 17 (12.6) 37 (17.6) 36 (14.6) 30 (10.8) 40 (11.8) 41 (10.3) 70 (15.7) 58 (15.3)
Renovascular & vascular
diseases
5 (5.0) 2 (1.5) 4 (3.0) 2 (1.0) 5 (2.0) 4 (1.4) 5 (1.5) 5 (1.3) 5 (1.1) 4 (1.1)
Congenital, familial, &
metabolic disorders
– 1 (0.7) – – 3 (1.2) 2 (0.7) – – – 2 (0.5)
Neoplasms 1 (1.0) – 1 (0.7) 2 (1.0) – – 2 (0.6) – 1 (0.2) 2 (0.5)
Others 24 (24.0) 51 (37.8) 49 (36.3) 80 (38.1) 91 (36.8) 122 (43.7) 137 (40.3) 172 (43.0) 200 (44.9) 146 (38.5)
Unknown 6 (6.0) 5 (3.7) 6 (4.4) 14 (6.7) 2 (0.8) 5 (1.8) 6 (1.8) 6 (1.5) 3 (0.7) 3 (0.8)
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Figure 18: One year adjusted patient survival by year of trans-
plantation for SLK and liver only recipients.
Cause of renal disease
The primary kidney disease of SLK recipients was listed
as ‘other’ in approximately 40% (Table 12). Since acute
renal failure and hepatorenal syndrome are not listed in-
dications for SLK transplantation, many of these SLK re-
cipients with a primary renal diagnosis listed as ‘other’
might have had acute renal failure or hepatorenal syn-
drome. Diabetes was the most common cause of chronic
renal disease in the liver transplant population, represent-
ing 11–18% of total SLK transplants. Tubular and intersti-
tial diseases accounted for 10–15% most recently. Other
diagnoses in 2008 such as polycystic renal disease, hy-
pertension and glomerular diseases accounted for 6.1%,
8.7% and 10.8%, respectively. The patients receiving SLK
represented by primary renal diagnoses not designated as
chronic renal disease precipitously declined from 200 to
146 transplants between 2007 and 2008. This decline rep-
resented a change from 44.9% of all SLK to 38.5%. The
most likely explanation is the reduction of transplants per-
formed for hepatorenal syndrome and acute renal failure
as would be expected from the selection changes under-
taken at many U.S. transplant centers after the consensus
conference on SLK in 2006, and other data supporting re-
visions of selection criteria for SLK.
Survival
One year adjusted patient survival for patients undergo-
ing liver transplant alone has generally increased over the
decade between 1999 and 2007 (Figure 9A and 9B). For
SLK transplantation, there was no such improvement in
patient survival (Figure 18). In fact, the patient survival of
SLK recipients in 2007 at 84.7% was almost the same as
that observed in SLK recipients in 1999 at 84.1%. The re-
flection of the selection changes that generally occurred in
2007 and 2008 will not impact the survival analyses until
a later date, and thus the impact of these actions will be
determined by future survival analyses. As expected, pa-
tients with HCV (n = 954) had a lower patient survival
after SLK compared to those without HCV (n = 1431)
(Figure 19).
Summary
The introduction of MELD and PELD for organ allocation in
2002 changed the dynamics of liver transplantation in the
United States. During the decade from 1999 through 2008,
the number of liver transplants increased and reached a
peak in 2006, and waiting time for liver transplantation,
especially for the sickest patients, decreased. The num-
ber of liver transplants for HCC increased significantly
over the decade after the introduction of MELD excep-
tion scores. Similarly, introduction of MELD increased the
number of SLK, since serum creatinine is a major deter-
minant of MELD score. Despite an increase in the re-
cipient comorbidities (severe obesity, diabetes, renal in-
sufficiency) and an increased DRI, there was a trend to-
ward a better 1-year graft and patient survival over the
decade with a decrease in retransplantation rates. These
trends are reassuring, but there was significant regional
variation in the waiting time and postliver transplant sur-
vival. Only 43% of recipients were transplanted within
Figure 19: Patient survival in HCV positive
(n = 954) and HCV negative (n = 1431) pa-
tients after SLK.
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90 days or less in Region 5, while 71% of liver recipi-
ents in Region 3 were transplanted within that time frame.
Similarly, there was considerable geographic variation in
1-year graft survival ranging from 73% in Maryland to 96%
in Arkansas. Such differences could not be explained by
yearly center volume as it had only a minimal impact on
outcomes. As described in previous reports (10), recipi-
ent race is an important predictor of survival, and we have
shown that there may be an interaction between recipi-
ent and donor race matching on posttransplant survival in
HCV positive recipients. These observations merit further
investigations.
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